



## **MSF Statement**

### **Agenda item 11.8 - Antimicrobial resistance: accelerating national and global responses**

*77<sup>th</sup> World Health Assembly, May 2024*

As a treatment provider in resource-scarce settings, MSF faces serious challenges addressing drug-resistant infections. Ahead of the UN High-level Meeting on Antimicrobial Resistance (AMR), we call on governments to prioritise the following actions:

First, **redress the stark inequities** in access to quality, person-centred healthcare that constrain many governments' ability to prevent, detect, and respond to AMR.

Second, ensure that **frameworks for accelerating national action plans** on AMR prioritise the needs of people living in low- and middle-income countries (LMICs), particularly in humanitarian contexts, with adequate and fairly apportioned funding among countries. Any **platform tasked with generating evidence** to inform action must engage civil society and affected communities to address the needs of those most impacted by AMR and least equipped with relevant data.

Lastly, **establish systems for universal and sustainable access** to AMR-related medical products. This entails identifying and addressing access gaps through geographically diversified manufacturing, strengthening forecasting and supply chain management, supporting pooled procurement mechanisms, and structuring and incentivising innovation in ways that are more collaborative and responsive to the need for timely and equitable access.